(Reuters) - The funding round launched by China to support its semiconductor industry is struggling in the initial phases to raise its target of 300 b.
U.S. health regulators declined to approve a nasal spray that would have been the first needle-free emergency treatment for allergic reactions and asked for further tests, a move that left its developer ARS Pharmaceuticals "very surprised". ARS Pharma's Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi's Auvi-Q filled with epinephrine, a life-saving drug used by people at risk of anaphylaxis and other allergic reactions. The U.S. Food and Drug Administration (FDA), in its so-called "Complete Response Letter", asked the company to complete a repeat-dose study on the treatment before a potential approval, rather than after as was mutually agreed in August, ARS Pharma said late on Tuesday.
U.S. health regulators declined to
approve a nasal spray that would have been the first needle-free
emergency treatment for allergic reactions and asked for further
tests, a move that left its.
Sept 19 - Canada s Unifor union said late on Monday that contract
negotiations with Ford Motor were continuing and advised
members to remain on shift unless they received.